{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:00:13Z","timestamp":1785859213347,"version":"3.56.0"},"reference-count":20,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To evaluate the efficacy and safety of poseltinib (formerly LY3337641\/HM71224), an irreversible covalent inhibitor of Bruton\u2019s tyrosine kinase in a 2-part, phase II trial (RAjuvenate; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02628028\">NCT02628028<\/jats:ext-link>) in adults with active rheumatoid arthritis (RA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>In Part A, 36 patients with mildly active RA were randomized 1:1:1:1 to oral poseltinib 5, 10, or 30 mg or placebo once daily for 4 weeks to assess safety and tolerability. No safety signals precluded moving to Part B, where 250 patients with moderate-to-severe RA were randomized 1:1:1:1 to oral poseltinib 5 mg (n = 63), 10 mg (n = 62), or 30 mg (n = 63), or placebo (n = 62) once daily for 12 weeks. Parts A and B permitted stable doses of background disease-modifying antirheumatic drugs. The primary endpoint in Part B was proportion of patients achieving 20% improvement in American College of Rheumatology criteria (ACR20) at Week 12. Logistic regression compared each poseltinib dose to placebo for primary and secondary endpoints. Nonresponder imputation was used for missing data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>After interim analysis showed low likelihood of demonstrating significant efficacy, the sponsor discontinued Part B of the study. One hundred and eighty-nine (76%) patients completed 12 weeks in Part B; 61 discontinued study treatment (27 [44%] due to study termination by sponsor). There was no statistically significant difference in ACR20 response between any dose of poseltinib and placebo at Week 12 (<jats:italic>P<\/jats:italic> &gt; 0.05 for all comparisons). Five serious adverse events occurred (n = 2, placebo; n = 3, 30 mg); there was 1 death due to a fall.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>While no safety findings precluded continuation, the study was terminated after interim data demonstrated low likelihood of benefit in RA.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.200893","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T22:35:24Z","timestamp":1608158124000},"page":"969-976","source":"Crossref","is-referenced-by-count":21,"title":["Safety and Efficacy of Poseltinib, Bruton\u2019s Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study"],"prefix":"10.3899","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5294-4503","authenticated-orcid":false,"given":"Mark C.","family":"Genovese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Spindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Sagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai Shan Melanie","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Witcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Barchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Nirula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"2022062305300679000_48.7.969.1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151132"},{"key":"2022062305300679000_48.7.969.2","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.481"},{"key":"2022062305300679000_48.7.969.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2013.04.007"},{"key":"2022062305300679000_48.7.969.4","doi-asserted-by":"publisher","DOI":"10.1177\/2040620714539906"},{"key":"2022062305300679000_48.7.969.5","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2012.670334"},{"key":"2022062305300679000_48.7.969.6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13075-016-0988-z","article-title":"HM71224, a novel Bruton\u2019s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis","volume":"18","author":"Park","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2022062305300679000_48.7.969.7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-017-1402-1","article-title":"HM71224, a selective Bruton\u2019s tyrosine kinase inhibitor, attenuates the development of murine lupus","volume":"19","author":"Kim","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2022062305300679000_48.7.969.8","first-page":"261","article-title":"Safety, pharmacokinetics and proof-of-mechanism of an oral Bruton\u2019s tyrosine kinase inhibitor HM71224 in healthy adult volunteers","volume":"74","author":"Lee","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022062305300679000_48.7.969.9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/annrheumdis-2014-eular.3058","article-title":"Safety, pharmacokinetics, pharmacodynamics, and food effect of an oral Bruton\u2019s tyrosine kinase inhibitor HM71224 in healthy subjects","volume":"73","author":"Yoon","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022062305300679000_48.7.969.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"2022062305300679000_48.7.969.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"2022062305300679000_48.7.969.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"2022062305300679000_48.7.969.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190008"},{"key":"2022062305300679000_48.7.969.14","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II Trial (ANDES Study)","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"2022062305300679000_48.7.969.15","unstructured":"Kivitz AJ , Gupta R , Valenzuela G , Smith E , Rehman Q , El Kadi H , A phase 2a, 4-week double-blind, proof-of-concept efficacy and safety study of CC-292 versus placebo as co-therapy with methotrexate in active rheumatoid arthritis (RA) [abstract]. Arthritis Rheumatol 2016;68 Suppl 10."},{"key":"2022062305300679000_48.7.969.16","unstructured":"ACP-196 versus placebo in subjects with rheumatoid arthritis on background methotrexate. ClinicalTrials.gov identifier: NCT02387762. [Internet. Accessed March 15, 2021.] Available from: clinicaltrials.gov\/ct2\/show\/NCT02387762"},{"key":"2022062305300679000_48.7.969.17","unstructured":"Efficacy and safety study of BMS-986142 in patients with moderate to severe rheumatoid arthritis. ClinicalTrials.gov identifier: NCT02638948. [Internet. Accessed March 15, 2021.] Available from: clinicaltrials.gov\/ct2\/show\/study\/NCT02638948"},{"key":"2022062305300679000_48.7.969.18","unstructured":"Safety and efficacy study of M2951 in participants with rheumatoid arthritis. ClinicalTrials.gov identifier: NCT02784106. [Internet. Accessed March 15, 2021.] Available from: clinicaltrials.gov\/ct2\/show\/NCT02784106"},{"key":"2022062305300679000_48.7.969.19","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Evobrutinib Phase 2 Study Group. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N Engl J Med"},{"key":"2022062305300679000_48.7.969.20","doi-asserted-by":"crossref","unstructured":"Isenberg D , Furie R , Jones N , Guibord P , Galanter J , Lee C , Efficacy, safety, and pharmacodynamic effects of the Bruton\u2019s tyrosine kinase inhibitor, fenebrutinib (GDC-0853), in moderate to severe systemic lupus erythematosus: results of a phase 2 randomized controlled trial [abstract]. Arthritis Rheumatol 2019;71 Suppl 10.","DOI":"10.1136\/annrheumdis-2020-eular.2949"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.200893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T12:33:19Z","timestamp":1655987599000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.200893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,1]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.3899\/jrheum.200893"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.200893","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,15]]}}}